Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature

Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials...

Descripción completa

Detalles Bibliográficos
Autores: Rodriguez-Otero, Paula, Victoria Mateos, Maria, Martinez-Lopez, Joaquin, Hernandez, Miguel T, Ocio, Enrique M, Rosinol, Laura, Martinez, Rafael, Teruel, Ana Isabel, Gutierrez, Norma C, Bargay Lleonart, Joan, Bengoechea, Enrique, Gonzalez, Yolanda, Perez de Oteyza, Jaime, Gironella, Mercedes, Nunez-Cordoba, Jorge M, Encinas, Cristina, Martin, Jesus, Cabrera, Carmen, Palomera, Luis, de Arriba, Felipe, Cedena, Maria Teresa, Puig, Noemi, Oriol, Albert, Paiva, Bruno, Blade, Joan, Lahuerta, Juan Jose, San Miguel, Jesus F
Tipo de recurso: artículo
Fecha de publicación:2019
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/22778
Acceso en línea:https://hdl.handle.net/20.500.12105/22778
Access Level:acceso abierto
Palabra clave:Humanos
Gammopatía Monoclonal de Relevancia Indeterminada
Anciano
Mieloma Múltiple
Femenino
Masculino
Aged
Male
Multiple Myeloma
Female
Humans
Monoclonal Gammopathy of Undetermined Significance
id ES_5b4eab520e19ac414f10b567df8e8d71
oai_identifier_str oai:repisalud.isciii.es:20.500.12105/22778
network_acronym_str ES
network_name_str España
repository_id_str
spelling Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signatureRodriguez-Otero, PaulaVictoria Mateos, MariaMartinez-Lopez, JoaquinHernandez, Miguel TOcio, Enrique MRosinol, LauraMartinez, RafaelTeruel, Ana IsabelGutierrez, Norma CBargay Lleonart, JoanBengoechea, EnriqueGonzalez, YolandaPerez de Oteyza, JaimeGironella, MercedesNunez-Cordoba, Jorge MEncinas, CristinaMartin, JesusCabrera, CarmenPalomera, Luisde Arriba, FelipeCedena, Maria TeresaPuig, NoemiOriol, AlbertPaiva, BrunoBlade, JoanLahuerta, Juan JoseSan Miguel, Jesus FHumanosGammopatía Monoclonal de Relevancia IndeterminadaAncianoMieloma MúltipleFemeninoMasculinoAgedMaleMultiple MyelomaFemaleHumansMonoclonal Gammopathy of Undetermined SignificanceDisease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) >= 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb >= 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.Nature Publishing Group20242024-09-1020192019-03-1820192019-03-18research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articlehttps://hdl.handle.net/20.500.12105/22778reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/227782026-06-12T12:43:37Z
dc.title.none.fl_str_mv Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
title Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
spellingShingle Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Rodriguez-Otero, Paula
Humanos
Gammopatía Monoclonal de Relevancia Indeterminada
Anciano
Mieloma Múltiple
Femenino
Masculino
Aged
Male
Multiple Myeloma
Female
Humans
Monoclonal Gammopathy of Undetermined Significance
title_short Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
title_full Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
title_fullStr Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
title_full_unstemmed Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
title_sort Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
dc.creator.none.fl_str_mv Rodriguez-Otero, Paula
Victoria Mateos, Maria
Martinez-Lopez, Joaquin
Hernandez, Miguel T
Ocio, Enrique M
Rosinol, Laura
Martinez, Rafael
Teruel, Ana Isabel
Gutierrez, Norma C
Bargay Lleonart, Joan
Bengoechea, Enrique
Gonzalez, Yolanda
Perez de Oteyza, Jaime
Gironella, Mercedes
Nunez-Cordoba, Jorge M
Encinas, Cristina
Martin, Jesus
Cabrera, Carmen
Palomera, Luis
de Arriba, Felipe
Cedena, Maria Teresa
Puig, Noemi
Oriol, Albert
Paiva, Bruno
Blade, Joan
Lahuerta, Juan Jose
San Miguel, Jesus F
author Rodriguez-Otero, Paula
author_facet Rodriguez-Otero, Paula
Victoria Mateos, Maria
Martinez-Lopez, Joaquin
Hernandez, Miguel T
Ocio, Enrique M
Rosinol, Laura
Martinez, Rafael
Teruel, Ana Isabel
Gutierrez, Norma C
Bargay Lleonart, Joan
Bengoechea, Enrique
Gonzalez, Yolanda
Perez de Oteyza, Jaime
Gironella, Mercedes
Nunez-Cordoba, Jorge M
Encinas, Cristina
Martin, Jesus
Cabrera, Carmen
Palomera, Luis
de Arriba, Felipe
Cedena, Maria Teresa
Puig, Noemi
Oriol, Albert
Paiva, Bruno
Blade, Joan
Lahuerta, Juan Jose
San Miguel, Jesus F
author_role author
author2 Victoria Mateos, Maria
Martinez-Lopez, Joaquin
Hernandez, Miguel T
Ocio, Enrique M
Rosinol, Laura
Martinez, Rafael
Teruel, Ana Isabel
Gutierrez, Norma C
Bargay Lleonart, Joan
Bengoechea, Enrique
Gonzalez, Yolanda
Perez de Oteyza, Jaime
Gironella, Mercedes
Nunez-Cordoba, Jorge M
Encinas, Cristina
Martin, Jesus
Cabrera, Carmen
Palomera, Luis
de Arriba, Felipe
Cedena, Maria Teresa
Puig, Noemi
Oriol, Albert
Paiva, Bruno
Blade, Joan
Lahuerta, Juan Jose
San Miguel, Jesus F
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Humanos
Gammopatía Monoclonal de Relevancia Indeterminada
Anciano
Mieloma Múltiple
Femenino
Masculino
Aged
Male
Multiple Myeloma
Female
Humans
Monoclonal Gammopathy of Undetermined Significance
topic Humanos
Gammopatía Monoclonal de Relevancia Indeterminada
Anciano
Mieloma Múltiple
Femenino
Masculino
Aged
Male
Multiple Myeloma
Female
Humans
Monoclonal Gammopathy of Undetermined Significance
description Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) >= 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb >= 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.
publishDate 2019
dc.date.none.fl_str_mv 2019
2019-03-18
2019
2019-03-18
2024
2024-09-10
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.12105/22778
url https://hdl.handle.net/20.500.12105/22778
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Nature Publishing Group
publisher.none.fl_str_mv Nature Publishing Group
dc.source.none.fl_str_mv reponame:Repisalud
instname:Instituto de Salud Carlos III (ISCIII)
instname_str Instituto de Salud Carlos III (ISCIII)
reponame_str Repisalud
collection Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408789541683200
score 15,811543

Similares en LA Referencia